Next Article in Journal
Age-Related Decline of Male Fertility: Mitochondrial Dysfunction and the Antioxidant Interventions
Next Article in Special Issue
Refining Glioblastoma Surgery through the Use of Intra-Operative Fluorescence Imaging Agents
Previous Article in Journal
Possible Association between the Use of Proton Pump Inhibitors and H2 Receptor Antagonists, and Esophageal Cancer: A Nested Case–Control Study Using a Korean National Health Screening Cohort
Previous Article in Special Issue
Pharmacokinetic Imaging Using 99mTc-Mebrofenin to Untangle the Pattern of Hepatocyte Transporter Disruptions Induced by Endotoxemia in Rats
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 15
Issue 5
10.3390/ph15050518
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Radiopharmaceutical Labelling for Lung Ventilation/Perfusion PET/CT Imaging: A Review of Production and Optimization Processes for Clinical Use

by
Frédérique Blanc-Béguin
1,*,
Simon Hennebicq
1,
Philippe Robin
1,
Raphaël Tripier
2,
Pierre-Yves Salaün
1 and
Pierre-Yves Le Roux
1
1
Univ Brest, UMR-INSERM 1304, GETBO, CHRU Brest, Médecine Nucléaire, Avenue Foch, 29200 Brest, France
2
Univ Brest UMR-CNRS 6521 (CEMCA), IFR 148, Avenue Le Gorgeu, 29200 Brest, France
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2022, 15(5), 518; https://doi.org/10.3390/ph15050518
Submission received: 16 March 2022 / Revised: 20 April 2022 / Accepted: 20 April 2022 / Published: 22 April 2022
(This article belongs to the Special Issue In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research)
Browse Figures
Review Reports Versions Notes

Abstract

:
Lung ventilation/perfusion (V/Q) positron emission tomography-computed tomography (PET/CT) is a promising imaging modality for regional lung function assessment. The same carrier molecules as a conventional V/Q scan (i.e., carbon nanoparticles for ventilation and macro aggregated albumin particles for perfusion) are used, but they are labeled with gallium-68 (68Ga) instead of technetium-99m (99mTc). For both radiopharmaceuticals, various production processes have been proposed. This article discusses the challenges associated with the transition from 99mTc- to 68Ga-labelled radiopharmaceuticals. The various production and optimization processes for both radiopharmaceuticals are reviewed and discussed for optimal clinical use.

1. Introduction

Lung ventilation-perfusion (V/Q) scintigraphy allows the regional lung function distribution of the two major components of gas exchanges, namely ventilation and perfusion, to be assessed [1]. Regional lung ventilation can be imaged after inhaling inert gases or radiolabelled aerosols that reach alveoli or terminal bronchioles. Regional lung perfusion can be assessed after intravenous injection of radiolabelled macroaggregated albumin (MAA) particles trapped during the first pass in the terminal pulmonary arterioles [2,3].
Pulmonary embolism (PE) diagnosis is the main clinical indication of lung V/Q scintigraphy in pulmonary embolism (PE) diagnosis. V/Q scanning was the first non-invasive test validated for PE diagnosis. The technique was then further improved with the introduction of single-photon emission computed tomography (SPECT) and, more recently, SPECT/computed tomography (CT) imaging [4]. There are many other clinical situations in which an accurate assessment of regional lung function may improve patient management besides PE diagnosis. This includes predicting post-operative pulmonary function in patients with lung cancer, radiotherapy planning to minimize the dose to the lung parenchyma with preserved function and reduce radiation-induced lung toxicities, or pre-surgical assessment of patients with severe emphysema undergoing a lung volume reduction surgery. However, although lung scintigraphy should play a central role in these clinical scenarios, its use has not been widely implemented in daily clinical practice [5]. One of the likely explanations could be the inherent technical limitations of SPECT imaging for the accurate delineation and quantification of regional ventilation and perfusion function [4].
Lung V/Q positron emission tomography (PET)/CT is a novel promising imaging modality for regional lung function assessment [6,7]. The technique has shown promising results in various clinical scenarios, including PE diagnosis [8], radiotherapy planning [9], or pre-surgical evaluation of lung cancer patients [10]. Several large prospective clinical trials are underway, such as (NCT04179539, NCT03569072, NCT04942275, and NCT05103670). The rationale is simple [5]. PET/CT uses the same carrier molecules as conventional V/Q scanning, i.e., carbon nanoparticles for ventilation imaging and MAA particles for perfusion imaging. Similar physiological processes are therefore assessed with SPECT or PET imaging. However, carrier molecules are labelled with gallium-68 (68Ga) instead of technetium-99m (99mTc), allowing the acquisition of images with PET technology. PET has technical advantages compared with SPECT, including higher sensitivity, higher spatial and temporal resolution, superior quantitative capability and much greater access to respiratory-gated acquisition [11].
This article discusses the challenges associated with the switch from 99mTc- to 68Ga-labelled V/Q radiopharmaceuticals. The various synthesis and optimization processes for both radiopharmaceuticals are reviewed and discussed, focusing on optimal clinical use.

2. Challenges of the Transition from 99mTc- to 68Ga-Labelled Radiopharmaceuticals for Lung Imaging

As the chemical and physical properties of 99mTc and 68Ga are different, the transition from V/Q scintigraphy to V/Q PET/CT implies some adaptation.
99mTc, a metallic radionuclide, is the most widely available isotope in diagnostic nuclear medicine. It is found in oxidation states −I to VII, but the technetium (Tc) complexes for medical applications are found mostly in oxidation state V [12]. 99mTc, which mainly decays (88%) with a half-life of 6.02 h by gamma emission (Eγ = 140 keV) to the ground state technetium-99 (99Tc), is obtained as 99mTcO4− from a molybdenum-99 (99Mo)/99mTc generator commercially available and compatible with the requirements of Good Manufacturing Practices (GMP). The Tc(VII) in 99mTcO4− has to be reduced to a lower oxidation state to produce a 99mTc-stable peptide complex or a reactive intermediate complex [13]. Tc(V) forms 5- or 6-coordinate complexes, always in the presence of multiple bond cores with heteroatoms such as oxygen (O), nitrogen (N) or sulfur (S), among which the most common in radiopharmaceuticals are the oxotechnetium and the nitridotechnetium cores [12].
The prevalent gallium (Ga) oxidation state in aqueous solution is +3, forming several gallate anions as gallium hydroxides Ga(OH)4− at pH superior to 7. Ga(III) is a hard acid and is strongly bound to ligands featuring multiple anionic oxygen donor sites according to HSAB (hard-soft acid-base). Still, some cases have shown it to have a good affinity for thiolates [14]. Ga(III) ions can form four, five and six bonds, explaining all the possible salts or chelates. 68Ga decays with a half-life of 67.71 min by positron emission (88.88%) and electron capture (11.11%) to the ground state zinc-68 (68Zn). It is obtained from a commercially available germanium-68 (68Ge)/68Ga generator, compatible with GMP requirements.
The first challenge of the switch from 99mTc- to 68Ga-labelled radiopharmaceuticals for lung V/Q imaging is to maintain the pharmacological properties of V and Q tracers. Both MAA and carbon nanoparticles labelled with 99mTc have been largely studied. They have been shown to have a biodistribution throughout the lungs that allow an accurate assessment of regional lung perfusion and ventilation function. The principle of lung V/Q PET/CT imaging is to assess similar physiological processes than with conventional V/Q scan, but with greater technology for image acquisition.
The technique needs to be easy to implement in nuclear medicine facilities to enable routine use. The preparation should be fast, simple, GMP-compliant and safe for the operators. Furthermore, radiopharmaceutical production should use unmodified commercially available kits of carrier molecules and similar equipment and devices as much as possible as those used for conventional V/Q scans.

3. Lung Perfusion Imaging

3.1. [99mTc]Tc-MAA

3.1.1. Chemical Aspects of [99mTc]Tc-MAA Particles

Among the various type of human serum albumin (HSA) available for radionuclide labeling, MAA is the most commonly used form in nuclear medicine facilities. The nature of the complex [99mTc]Tc-MAA has not been fully elucidated. It was hypothesized that the labelling of proteins with 99mTcO4− involved reduction of the anionic Tc(VII) to a cationic Tc by the tin Sn(II) contained in the commercial kit, which was then complexed with electron-donating groups [15,16,17]. Some authors have assumed that 99mTcO4− reduced by the Sn(II)- albumin aggregates probably formed a (Tc = O)3+ complex with the aggregates [15]. More recently, high positive cooperativity was shown between 99mTc and MAA, although MAA particles did not seem to have binding pockets [18,19]. Moreover, it has been shown that the speed of radiolabelling increased from HAS to albumin nanocolloids (NC) to MAA due to the greater reaction surface [18]. This result agreed with the hypothesis, which assumed that in HAS labelling kits, Sn2+ may be enclosed in the tertiary structure of the protein and that it may take some time for the 99mTcO4− added to diffuse the site of Sn2+ for reduction reaction [17]. Furthermore, MAA has very complex shapes with larger surfaces than a spherical shape (as for NC) of equivalent diameter, enhancing the reactivity properties [18,19].
Whatever the exact nature of the link between 99mTc and MAA, the complex [99mTc]Tc-MAA demonstrates high stability as more than 90% of the radioactivity is still associated with the MAA after 24h of in vitro incubation in whole human blood at 37 °C [20].

3.1.2. Technical Aspects: [99mTc]Tc-MAA Preparation

[99mTc]Tc-MAA particles are manually prepared by introducing a 99mTc solution in a commercially available MAA kit. The 99mTc is obtained from a 99Mo/99mTc generator as sodium pertechnetate (99mTcO4−, Na+). The MAA labelling with 99mTc, which occurred at pH 6, is a simple and fast (about 15 min) process, which allows the production of GMP [99mTc]Tc-MAA without heating step [18].
Before intravenous administration to the patients, the [99mTc]Tc-MAA suspensions are tested according to the standards mentioned by the kit supplier for clinical use. The radiochemical purity (RCP) is generally controlled using instant thin layer chromatography (iTLC), and the radioactivity distribution is assessed by filtration of the [99mTc]Tc-MAA suspension through a 3-µm pore size membrane. The results are obtained by measuring filter and filtrate radioactivity. The radionuclidic purity and the pH have to be controlled as well. As MAA are large particles, [99mTc], Tc-MAA must be resuspended by gentle agitation before dispensing.

3.1.3. Pharmacological Aspects

In a [99mTc]Tc-MAA suspension, the average particle size is 20–40 µm, and 90% have a size between 10 and 90 µm. There should be no particles larger than 150 µm [21]. [99mTc]Tc-MAA particles reach the lung via the pulmonary arterial circulation. Due to the size of the alveolar capillaries (5.5 µm on average), the [99mTc]Tc-MAA does not reach the alveolar capillaries but largely accumulates in the terminal pulmonary arterioles. Particles inferior to 10 µm may pass through the lungs and then phagocytose by the reticuloendothelial system [21]. According to the requirement of the MAA suppliers, the number of MAA particles injected should range from 60,000 to 700,000 to obtain uniform distribution of activity reflecting regional perfusion (for over 280 billion pulmonary capillaries and 300 million pre-capillary arterioles) [22].
Many studies have shown the suitability of the [99mTc]Tc-MAA suspension to perform pulmonary perfusion scintigraphy. In rabbits, it has been shown that more than 90% of the activity was found in the lungs within a few minutes of administration and that greater than 80% of the activity remained in the lungs over the first hour of the study [20]. Malone et al. assessed the biodistribution of MAA particles in humans [23]. A total of 98% of activity was measured in the lungs immediately after injection. The removal of activity from the lungs followed an approximately bi-exponential form with the first phase in which 56% of the components had an effective half-life of 0.88 ± 0.16 h and the second phase in which 44% of the components had a half-life of 4.56 ± 0.39 h. Moreover, 3 h after injection, the [99mTc]Tc-MAA uptake in the kidneys and the bladder was 3.6 ± 2.1% and 5.1 ± 4.0%, respectively [23].

3.2. [68Ga]Ga-MAA

3.2.1. Chemical Aspects of [68Ga]Ga-MAA Particles

MAA labelling with 68Ga has been proposed using bifunctional chelators such as EDTA or DTPA, forming quite stable and inert chelates [24,25]. However, direct labelling was performed by most groups. Direct labelling uses a co-precipitation of 68Ga(III) and albumin particles [26,27]. Mathias et al. hypothesized that 68Ga was adsorbed to the surface of the MAA particles after hydrolysis to insoluble gallium hydroxide without excluding specific interactions of Ga(III) ion with ion pairs exposed at the particle surface [28]. As Ga is present as Ga(OH)4− at a basic pH, 68Ga does not bind to MAA at a pH above 7. The MAA behavior matches with solvent-exposed glutamate and aspartate amino acids, which should be binding sites for multivalent cations with low affinity and low cation specificity [18]. Furthermore, Jain et al. found that stannous chloride (SnCl2) present in the MAA kits for the reduction of 99mTc had a strong influence on [68Ga]Ga-MAA formation (radiochemical yield, mean particle diameter, serum stability), suggesting that Sn could be linked to MAA or 68Ga [29]. More recently, it has been assumed that MAA has multiple affinity binding sites for 68Ga [18]. Moreover, during 99mTc and 68Ga competition evaluation for MAA binding sites, MAA showed no discrimination between 99mTc and 68Ga coherently without a binding pocket [18].

3.2.2. Technical Aspects: [68Ga]Ga-MAA Preparation

[99mTc]Tc-MAA preparation is a manual and simple process involving only 2 steps: generator elution and mixing the eluate with the MAA. In contrast, because of the chemical properties of 68Ga, at least four steps are required to label MAA particles with 68Ga: 68Ge/68Ga generator elution, mixing the 68Ga eluate with the MAA, heating the reaction medium and the purification of the [68Ga]Ga-MAA. The key steps of MAA labelling with 68Ga are presented in Figure 1.
Table 1 summarizes the various [68Ga]Ga-MAA preparation processes described in the literature. The main diverging points of the preparations include (1) the choice of MAA particles, (2) the need for a 68Ga eluate pre-purification, (3) the labelling conditions (pH, heating temperature and time), (4) the [68Ga]Ga-MAA suspension purification, and (5) the automation of the process (Figure 1).
  • MAA
As shown in Table 1, almost all authors used commercial kits available to prepare [99mTc]Tc-MAA for labelling MAA particles with 68Ga. The use of commercially available kits is an important consideration to facilitate the implementation of the technique in nuclear medicine facilities. However, commercially available MAA kits contain SnCl2 and free albumin. Consequently, many groups carried out MAA labelling with washed MAA to remove the excess of free albumin and SnCl2 (stannous chloride), which is usually used as a reduction component, from the kit and thus improve the labelling yields (Table 1). Ayşe et al. obtained a better final product RCP by washing the MAA particles before the labelling (RCP = 99.0 ± 0.1%) rather than not washing (RCP = 95.0 ± 0.1%) [38]. On the other hand, Mueller et al. found no significant difference in the radiolabelling yields using non-washed and pre-washed MAA (80% and 75%, respectively) [35]. In studies that used unmodified commercially available MAA kits, radiolabelling yields were consistently superior to 75.0% (Table 1) [28,35,39]. Furthermore, Jain et al. found lower radiolabelling yields using in-house synthesized MAA without SnCl2 than MAA with SnCl2 (49.9 ± 1.3% and 84.5 ± 5.3%, respectively). They found that stannous chloride present in the MAA kits used had a strong influence on the [68Ga]Ga-MAA formation (radiochemical yield, mean particle diameter, serum stability), suggesting that Sn could be linked to MAA or 68Ga [29]. Consequently, using unmodified non-washed commercially available MAA kits produced for 99mTc seems to be a suitable solution for [68Ga]Ga-MAA labelling;
  • 68Ga eluate
68Ga eluate obtained from currently available generators are contaminated with long-lived parent nuclide 68Ge and cationic metal ion impurities such as titanium (Ti)4+ from the column material, zinc (Zn)2+ from the decay of 68Ga or iron (Fe)3+. These impurities might compete with 68Ga in the complexation reaction [40,41].
Pre-purification of the eluate has been proposed by several groups, with various methods such as anion exchange chromatography, cationic cartridge, fractionation or eluate pre-concentration (Table 1) proposed to overcome this issue. Most groups performed an eluate pre-purification using an SCX cartridge or an equivalent pre-conditioned with hydrochloric acid (HCl) and water (Table 1).
In contrast, a few groups did not perform 68Ga eluate pre-purification before MAA labelling and obtained 68Ge impurity levels lower than 0.0001% and radiolabelling yields superior to 96.0% (Table 1) [28,29,34,39]. Based on these results and the fact that this is time-consuming, the pre-purification of the 68Ga eluate does not seem mandatory and could be avoided for [68Ga]Ga-MAA preparation.
  • Labelling conditions
The three key points of the MAA labelling with 68Ga are the pH, the heating temperature, and the reaction medium’s heating time (Figure 1).
Among the various [68Ga]Ga-MAA labelling processes published, the labelling pH ranges from 3 to 6.5, with the radiolabelling yield varying from 65.0 to 97.4% (decay corrected or not) (Table 1). The optimal pH range seems to be between 4 and 6.5, where 68Ga is a water-soluble cation [14]. Importantly, it has been shown that Ga does not bind to albumin at a pH above 7 [19]. For assessing the optimal pH for the labelling reaction, three buffers or equivalents have been used: acetate buffer, sodium acetate solution and HEPES buffer (Table 1). HEPES and acetate buffers are biocompatible with no toxicity issue [40]. They have demonstrated better characteristics to stabilize and prevent 68Ga(III) precipitation and colloid formation [40]. Nevertheless, in contrast to sodium acetate, HEPES is not approved for human use, and thus, purification and additional quality control analyses are required, resulting in further time and resource consumption [40].
The labelling temperatures reported in the literature ranged from 40 °C to 115 °C (Table 1). Whatever the labelling conditions, the radiolabelling yields were superior to 75.0% in all but one study (Table 1). Several studies have tested various labelling conditions and obtained increasing radiolabelling yield by increasing the heating temperature (from 25 to 100 °C, pH: 4–6) [29,38]. On the other hand, low heating temperature (40–70 °C) has been described to preserve MAA structure and size because high temperatures may induce the rupture of bigger macroaggregates [34,36,39]. Accordingly, the heating temperature range seems quite large, as long as MAA integrity is maintained.
Finally, the labelling heating time ranged from 5 to 20 min (Table 1). Some studies have compared various heating times (from 3 to 50 min) and found higher labelling yields with heating times between 7 and 20 min [31,38,39]. Due to the short half-life of 68Ga and for practical considerations, the heating step should be as short as possible.
  • [68Ga]Ga-MAA purification
Many authors have shown that the final product RCP was improved by performing a purification step at the end of the labelling (Table 2). Various processes were used to purify [68Ga]Ga-MAA suspension. The most commonly used process was to wash the labelled MAA with saline and centrifuge to isolate [68Ga]Ga-MAA particles. Another process was to increase the reaction mixture to 10 mL with sterile water at the end of the heating step and to pass the suspension through a Sep-Pak C18 cartridge. Then, the cartridge was washed two times with sterile water. The RCP of the obtained final product was superior to 97% (Table 2).
While purification processes have only been manual to date, an innovative automated procedure was recently proposed for the purification step using a low protein-binding filter. At the end of the heating step, the reaction medium was passed through the filter from the bottom. Then, [68Ga]Ga-MAA was removed from the filter and transferred into the final vial by passing 10 mL of saline from the top to the bottom of the filter (see Figure 2) [39]. The RCP of the obtained [68Ga]Ga-MAA suspension was 99.0 ± 0.6%.
  • Manual or Automated Process
Most of the [68Ga]Ga-MAA preparation processes described in the literature were manual and were carried out in 20 to 40 min (See Table 1) [28,31,32]. Mueller et al. showed that an automated process reduced the preparation time from 20 to 14 min [35]. A few automated processes were described in the literature to perform the synthesis from the elution to the end of the heating steps (see Table 1). More recently, a fully automated process has been proposed, including both MAA labelling and [68Ga]Ga-MAA purification, which was carried out in 15 min (see Table 1 and Table 2) [39]. To the best of our knowledge, this is the only fully automated process to date.

3.2.3. Pharmacological Aspects

An important challenge of the switch from 99m Tc- to 68Ga-labelled MAA is maintaining the pharmacological properties of particles to ensure similar biodistribution throughout the terminal pulmonary arterioles. Accordingly, the key parameter is the particle size, which should range between 10.0 and 90.0 µm, with no particles size superior to 150.0 µm. On the other hand, particles should not be inferior to 10.0 µm because the target organs would be the reticuloendothelial system and the bones instead of the lungs [22]. Most of the literature data reported a mean diameter ranging from 10 to 90 µm (15.0–75.0 µm for Blanc-Béguin et al., 52.9 ± 15.2 for Jain et al. and 43.0–51.0 for Canziani et al.) (Table 3) [18,29,39]. Furthermore, all published data on [68Ga]Ga-MAA described a preserved structure of radiolabelled particles, whatever the labelling conditions (see Table S1).
Hence, [99mTc]Tc-MAA and [68Ga]Ga-MAA particles have similar sizes and structures. The number of [68Ga]Ga-MAA particles injected should range from 60,000 to 700,000, no differently from [99mTc]Tc-MAA, to obtain uniform distribution of activity reflecting regional perfusion.
All studies that assessed the biodistribution of labelled MAA particles in the animals described an almost complete retainment of activity in the lungs from 5 min to 30, 45, 60 min, or 4 h after the injection of [68Ga]Ga-MAA particles, and very low activity in other organs, especially in the liver [22,29,33,34]. Indeed, experiments performed with rats or mice have shown that more than 80% of the injected activity was located in the lungs from 15 min to 4 h post-injection [22,29,34]. In female wild-type rats, the peak of activity occurred 1 min and 35 min post-injection in the kidneys and bladder, respectively, whereas it was from 10 to 20 min in the lungs [22]. In Sprague-Dawley rats, less than 2% of the injected dose per organ (ID/o) activity was measured in other organs from 2 to 4 h post-[68Ga]Ga-MAA administration in the tail vein [34]. It is noteworthy that, as compared with the [99mTc]Tc-MAA, [68Ga]Ga-MAA exhibited better in vivo stability after intravenous injection in Sprague-Dawley rats [34]. Indeed, the percentage of decay-corrected ID/o (DC-ID/o) of [68Ga]Ga-MAA located in the lung did not change over the study period, i.e., the 4 h following the injection (98.6 ± 0.7 at 2 h and 98.6 ± 0.1 at 4h), whereas the % DC-ID/o of [99mTc]Tc-MAA located in the lung decreased from 86.6 ± 0.7 at 2 h to 79.2 ± 1.5 at 4 h [34]. After injection in the rat tail vein, the main activity was extracted by the kidneys to the bladder, and the free 68Ga remained in the blood after two and four hours (84.9 ± 4.5% and 63.1 ± 3.9% of DC-ID/o, respectively), presumably as 68Ga native transferrin complex [22,34].
68Ga(III) has a high binding affinity to the blood serum protein transferrin (log K1 = 20.3). The main requirement for [68Ga]Ga-MAA stability is thermodynamic stability towards hydrolysis and formation of Ga(OH)3 [42]. As shown in Table 3, whatever the labelling conditions, the obtained [68Ga]Ga-MAA suspension had at least a 45 min in vitro stability in animal serum or plasma, which is largely sufficient given that images are acquired immediately after injection and that the acquisition time is approximately 5 min [33].
To the best of our knowledge, no data were published on the biodistribution of [68Ga]Ga-MAA in humans. However, Ament et al., who performed an exploratory study on five patients with clinical suspicion of PE who underwent V/Q PET/CT, have observed that perfusion imaging was homogeneous in most cases [33]. No significant retention and no visual uptake of [68Ga]Ga-MAA particles in the liver were detectable [33].
However, many clinical studies reported consistent activity distribution on PET imaging in various pulmonary conditions after injection of [68Ga]Ga-MAA [1,5,8,33,35,43].

4. Lung Ventilation Imaging

4.1. Aerosolized 99mTc-Labelled Carbon Nanoparticles (Technegas)

4.1.1. Physical and Chemical Aspects

99mTc-labelled carbon nanoparticles consist of primary hexagonally structured carbon nanoparticles, which can agglomerate into larger secondary aggregates. Primary nanoparticles are structured with graphite planes oriented parallel to the technetium surface to form nanoparticles with a thickness of about 5 nm [44]. Few data are available about the link between 99mTc and carbon nanoparticles. It was hypothesized that Tc7+ obtained from a 99Mo/99mTc generator was reduced at the crucible interface, resulting in native metal Tc which co-condensates with carbon species once in the vapor phase [44].
Some authors have hypothesized that 99mTc-labelled carbon nanoparticles consisted of 99mTc atoms trapped by a structure similar to a fullerene cage [45,46]. Indeed, Mackey et al. have demonstrated the presence of fullerenes during the generation of the aerosolized 99mTc-labelled carbon nanoparticles available to form metallofullerenes with the 99mTc atom attached either exohedrally or endohedrally to the fullerene molecules [46]. However, this hypothesis was controversial especially because of the hexagonal platelet structure of the labelled carbon nanoparticles [44].

4.1.2. Technical Aspects

The 99mTc-labelled carbon nanoparticle production is a simple process that requires relatively little material: a 99Mo/99mTc generator, a Technegas generator (Cyclomedica Pty Ltd., Kingsgrove, Australia) and a pure argon bottle. There are three main stages in 99mTc-labelled carbon nanoparticle production: the loading of the crucible, the simmer stage and the burning stage.
  • Crucible loading
Using a syringe with a needle, 0.14 mL to 0.30 mL (140–925 MBq) of 99mTc eluate is introduced in a graphite crucible previously humidified with 99% ethanol to increase its wettability and placed between the generator electrodes [6,47,48,49,50,51]. As the volume of the crucible is limited to 0.14 mL or 0.30 mL according to the supplier, it is possible to perform several crucible loadings to introduce all the 99mTc eluate needed;
  • Simmer stage
The simmer stage, performed immediately after the crucible loading, reduces 99mTc7+ to metallic 99mTc under a pure argon atmosphere [44]. The use of pure argon is a determining parameter for the structure and the physical properties of the 99mTc-labelled carbon nanoparticles [45,48,52,53,54]. During the simmer stage, the graphite crucible is heated for 6 min at 70 °C. However, it has been shown that increasing the number of simmers increases the median size of the 99mTc-labelled carbon nanoparticles [45];
  • Burning stage
The simmer cycle is followed by the crucible heating to 2550 °C ± 50 °C for 15 s. Metallic Tc and carbon species are vaporized and co-condensed during this burning stage to obtain aerosolized 99mTc-labelled carbon nanoparticles [44]. At the end of this stage, the switching off of the Technegas generator fills the 6 L chamber with aerosolized 99mTc-labelled carbon nanoparticles ready for use via inhalation by the patient.
All process parameters (heating temperature and time) used for clinical production are fixed. The machine allows a 10 min window in which the 99mTc-labelled carbon nanoparticles may be administered to the patient. However, the longer the administration delay is, the higher the median size of the particles is [45,51].

4.1.3. Pharmacological Aspects

The size of primary carbon nanoparticles ranges from 5 to 60 nm, while the size of the aggregates is approximately 100–200 nm (See Table 4). Hence, aerosolized 99mTc-labelled carbon nanoparticles are considered an ultrafine aerosol with ventilation properties similar to radioactive gasses, such as krypton-81m (81mKr) and xenon-133 (133Xe) [21,47,48,50,51,55,56,57]. Many authors agree on the mainly alveolar deposition of the 99mTc-labelled carbon nanoparticles and the stability of the nanoparticles in the lungs over time [21,45,49,57,58].

4.2. Aerosolized 68Ga-Labelled Carbon Nanoparticles

4.2.1. Physical and Chemical Aspects

The physical properties of aerosolized particles are important parameters in determining their penetration, deposition, and retention in the respiratory tract. The physical properties of 68Ga-labelled carbon nanoparticles, prepared using a Technegas generator in the usual clinical way, were recently assessed [60]. 68Ga-labelled carbon nanoparticles demonstrated similar properties as 99mTc-labelled carbon nanoparticles, with primary hexagonally shaped and layered structured particles [60]. Although the chemical process of labelling carbon nanoparticles with 68Ga and the exact chelation structure of 68Ga in carbon nanoparticles are unknown, the physical properties of 68Ga-labelled carbon nanoparticles suggest a method of labelling similar to labeling with 99mTc.

4.2.2. Technical Aspects

In contrast with MAA labelling, the process for 99mTc-labelled carbon nanoparticle preparation is very similar across studies in the literature. 68Ga-labelled carbon nanoparticles are produced using an unmodified Technegas generator and following the same stages as for the preparation of 99mTc-labelled carbon nanoparticles: the crucible loading with an eluate volume range from 0.14 mL to 0.30 mL, the simmer stage and the burning stage with similar heating time and temperature [6,7,33,60,61,62]. The only difference is the nature of the eluate, which is gallium-68 chloride (68GaCl3) instead of 99mTcO4−, Na+. Few authors performed an eluate pre-concentration using an anion exchange cartridge or by fractionating to purify and reduce the volume of the eluate [33,62]. However, 68Ga-labelled carbon nanoparticles obtained using an unmodified eluate from the 68Ge/68Ga generator demonstrated similar physical properties as 99mTc-labelled carbon nanoparticle properties and were suitable for pulmonary ventilation PET/CT [6,7,60,61].

4.2.3. Pharmacological Aspects

From the pharmacological point of view, an important parameter of the switch from lung ventilation SPECT to PET/CT is to maintain the physical properties of aerosolized carbon nanoparticles to ensure similar alveolar deposition and stability in the lungs.
The size is a key factor in determining the degree of aerosol particle penetration in the human pulmonary tract [55]. To the best of our knowledge, only one recently published work has studied the physical properties of 68Ga-labelled carbon nanoparticles, and few pharmacological data are available in the literature. However, it was reported that using an unmodified Technegas generator, the mean diameter of primary 68Ga-labelled carbon nanoparticles was in the same range as primary 99mTc-labelled carbon nanoparticles (22.4 ± 10.0 nm and 20.9 ± 7.2 nm, respectively) with similar agglomeration into larger secondary aggregates measuring several hundreds of nm [60].
These results suggested similar lung distribution of 99mTc- and 68Ga-labelled carbon nanoparticles, as confirmed by a study on healthy piglets [62]. Later, V/Q PET performed in Sprague-Dawley rats reported complete incorporation of 68Ga-labelled carbon nanoparticles in the lungs without extrapulmonary activity (urinary bladder, abdomen, blood pool) [33]. Moreover, animal studies performed with aerosolized 68Ga-labelled carbon nanoparticles have demonstrated greater differences between poorly and well-ventilated regions, suggesting higher resolution than 99mTc-labelled carbon nanoparticles [62].
Moreover, in healthy human volunteers, the activity distribution in the lungs after inhalation of 68Ga-labelled carbon nanoparticles was intense, without bronchial deposit 15 min after the inhalation. Furthermore, the activity (decay corrected) over the lung was constant at 3.5 h without elimination via blood, urine (only trace radioactivity in urine bladder was observed) or feces suggesting the stability of the deposition of 68Ga-labelled carbon nanoparticles over this time [7]. Another exploratory study performed on five patients with clinical suspicion of PE observed homogeneous ventilation imaging in two cases and inhomogeneous accumulation with central deposition of labelled carbon nanoparticles in three cases [33].
Finally, many clinical studies reported consistent activity distribution in the lungs on PET imaging in various pulmonary conditions after inhalation of 68Ga-labelled carbon nanoparticles [5,6,8,33].

5. Practical Considerations for an Optimal Clinical Use

Lung V/Q PET/CT is a promising imaging modality for regional lung function assessment. Indeed, PET imaging has great technical advantages over SPECT imaging (higher sensitivity, spatial and temporal resolution, superior quantitative capability, easier to perform respiratory-gated acquisition). PET may also be a useful alternative to SPECT imaging in a 99mTc shortage. The success of the switch from conventional scintigraphy to PET imaging, and therefore from 99mTc- to 68Ga-labelled radiopharmaceuticals, relies on two main factors: preserving the pharmacological properties of the labelled MAA and carbon nanoparticles, whose biodistribution is well known; and facilitating the implementation in nuclear medicine departments. In that respect, several studies have been conducted on the production of both perfusion and ventilation 68Ga-labelled radiopharmaceuticals, which have led to simplification, optimization and, more recently, automation of the processes.
For lung perfusion PET/CT imaging, various processes have been used for [68Ga]Ga-MAA labelling, with different options in the key steps of the preparation, including the choice of MAA particles, the need for 68Ga eluate pre-purification, the labelling conditions or the [68Ga]Ga-MAA suspension purification. However, simpler processes appear to be suitable for optimal clinical use. This includes using a non-modified commercially available MAA kit, with no need for a 68Ga eluate pre-purification, use of an easy to use buffer such as sodium acetate solution, and a short reaction medium heating time (5 min). Automated processes have been developed to facilitate processing time and reduce the radiation dose to the operator. Thus, a simple and fast (15 min) automated GMP compliant [68Ga]Ga-MAA synthesis process was proposed, using a non-modified MAA commercial kit, a 68Ga eluate without pre-purification and including an innovative process for [68Ga]Ga-MAA purification, which maintains the pharmacological properties of the tracer and provided labelling yields >95% [39]. Moreover, whatever the labelling conditions, the obtained [68Ga]Ga-MAA suspension was described to be stable in 0.9% sodium chloride for at least one hour [35,39]. Given the radioactive concentration of [68Ga], Ga-MAA obtained at the end of the synthesis (i.e., from 300MBq/10 mL to 900 MBq/10 mL according to the age of the 68Ge/68Ga generator) and the dose injected (i.e., around 50 MBq), up to 6 perfusion PET/CT scans can be performed with one synthesis [5,6,39,63].
For lung ventilation PET/CT imaging, preparing and administering aerosolized 68Ga-labelled carbon nanoparticles is very straightforward. The process is very similar to the production of 99mTc-labelled carbon nanoparticles and, therefore, fairly easy to implement in nuclear medicine facilities. Indeed, adding a 68Ga eluate instead of 99mTc eluate in the carbon crucible of an unmodified commercially available Technegas™ generator provides carbon nanoparticles with similar physical properties. Furthermore, recently, an automated process included a step to fractionate the 68Ga eluate into two samples, one for [68Ga]Ga-MAA labelling and the other for aerosolized 68Ga-labelled carbon nanoparticle production, which has been developed [39].
Besides radiopharmaceutical production, many factors may facilitate the implementation of V/P PET/CT imaging in nuclear medicine facilities. 68Ge/68Ga generators are increasingly available in the nuclear medicine departments due to 68Ga tracers for neuroendocrine tumors and prostate cancer imaging. PET/CT cameras are also increasingly accessible due to the development of digital PET/CT cameras and might be total-body PET/CT in the future. Most nuclear medicine facilities already have the necessary equipment to carry-out V/P PET/CT imaging, including carbon nanoparticle generators and MAA kits. Automating the MAA labelling is now possible; commercial development of ready-to-use sets for automated synthesis radiolabelling of 68Ga-MAA would be of interest.
In conclusion, recent data support the ease of using well-established carrier molecules and 68Ga to enable the switch from SPECT to PET imaging for regional lung function. The technology may be easily implemented in most nuclear medicine facilities and open perspectives for the improved management of patients with lung disease.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph15050518/s1, Table S1: [68Ga]Ga-MAA particles size and biodistribution study according to the various authors.

Author Contributions

Conceptualization, P.-Y.L.R. and F.B.-B.; formal analysis, F.B.-B.; data curation, F.B.-B.; writing—original draft preparation, F.B.-B. and P.-Y.L.R.; writing—review and editing, F.B.-B., S.H., P.R., R.T., P.-Y.S. and P.-Y.L.R.; visualization, F.B.-B. and P.-Y.L.R.; supervision, P.-Y.L.R., P.R. and P.-Y.S.; project administration, P.-Y.L.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Le Roux, P.Y.; Siva, S.; Steinfort, D.P.; Callahan, J.; Eu, P.; Irving, L.B.; Hicks, R.J.; Hofman, M.S. Correlation of 68Ga Ventilation-Perfusion PET/CT with Pulmonary Function Test Indices for Assessing Lung Function. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2015, 56, 1718–1723. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Bajc, M.; Schumichen, C.; Gruning, T.; Lindqvist, A.; Le Roux, P.Y.; Alatri, A.; Bauer, R.W.; Dilic, M.; Neilly, B.; Verberne, H.J.; et al. EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 2429–2451. [Google Scholar] [CrossRef] [Green Version]
  3. Le Roux, P.Y.; Blanc-Beguin, F.; Bonnefoy, P.B.; Bourhis, D.; Camilleri, S.; Moreau-Triby, C.; Pinaquy, J.B.; Salaün, P.Y. Guide pour la re’ daction de protocoles pour la scintigraphie pulmonaire. Méd. Nucl. 2021, 45, 8. [Google Scholar] [CrossRef]
  4. Le Roux, P.Y.; Robin, P.; Salaun, P.Y. New developments and future challenges of nuclear medicine and molecular imaging for pulmonary embolism. Thromb. Res. 2018, 163, 236–241. [Google Scholar] [CrossRef]
  5. Le Roux, P.Y.; Hicks, R.J.; Siva, S.; Hofman, M.S. PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA. Semin. Nucl. Med. 2019, 49, 71–81. [Google Scholar] [CrossRef] [PubMed]
  6. Hofman, M.S.; Beauregard, J.M.; Barber, T.W.; Neels, O.C.; Eu, P.; Hicks, R.J. 68Ga PET/CT ventilation-perfusion imaging for pulmonary embolism: A pilot study with comparison to conventional scintigraphy. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2011, 52, 1513–1519. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Kotzerke, J.; Andreeff, M.; Wunderlich, G. PET aerosol lung scintigraphy using Galligas. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 175–177. [Google Scholar] [CrossRef] [PubMed]
  8. Le Roux, P.Y.; Iravani, A.; Callahan, J.; Burbury, K.; Eu, P.; Steinfort, D.P.; Lau, E.; Woon, B.; Salaun, P.Y.; Hicks, R.J.; et al. Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: Results of the PECAN pilot study. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 1596–1604. [Google Scholar] [CrossRef] [PubMed]
  9. Siva, S.; Thomas, R.; Callahan, J.; Hardcastle, N.; Pham, D.; Kron, T.; Hicks, R.J.; MacManus, M.P.; Ball, D.L.; Hofman, M.S. High-resolution pulmonary ventilation and perfusion PET/CT allows for functionally adapted intensity modulated radiotherapy in lung cancer. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2015, 115, 157–162. [Google Scholar] [CrossRef]
  10. Le Roux, P.Y.; Leong, T.L.; Barnett, S.A.; Hicks, R.J.; Callahan, J.; Eu, P.; Manser, R.; Hofman, M.S. Gallium-68 perfusion positron emission tomography/computed tomography to assess pulmonary function in lung cancer patients undergoing surgery. Cancer Imaging Off. Publ. Int. Cancer Imaging Soc. 2016, 16, 24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Hicks, R.J.; Hofman, M.S. Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat. Rev. Clin. Oncol. 2012, 9, 9. [Google Scholar] [CrossRef] [PubMed]
  12. Papagiannopoulou, D. Technetium-99m radiochemistry for pharmaceutical applications. J. Label. Compd. Radiopharm. 2017, 60, 502–520. [Google Scholar] [CrossRef]
  13. Liu, S.; Edwards, D.S. 99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals. Chem. Rev. 1999, 99, 2235–2268. [Google Scholar] [CrossRef]
  14. Wadas, T.J.; Wong, E.H.; Weisman, G.R.; Anderson, C.J. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem. Rev. 2010, 110, 2858–2902. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Dewanjee, M.K. The chemistry of 99mTc-labeled radiopharmaceuticals. Semin. Nucl. Med. 1990, 20, 5–27. [Google Scholar] [CrossRef]
  16. Lin, M.S.; Winchell, H.S.; Shipley, B.A. Use of Fe(II) or Sn(II) alone for technetium labeling of albumin. J. Nucl. Med. 1971, 12, 8. [Google Scholar]
  17. Vanbilloen, H.P.; Verbeke, K.A.; De Roo, M.J.; Verbruggen, A.M. Technetium-99m labelled human serum albumin for ventriculography: A comparative evaluation of six labelling kits. Eur. J. Nucl. Med. 1993, 20, 465–472. [Google Scholar] [CrossRef] [PubMed]
  18. Canziani, L.; Marenco, M.; Cavenaghi, G.; Manfrinato, G.; Taglietti, A.; Girella, A.; Aprile, C.; Pepe, G.; Lodola, L. Chemical and Physical Characterisation of Macroaggregated Human Serum Albumin: Strength and Specificity of Bonds with 99mTc and 68Ga. Molecules 2022, 27, 404. [Google Scholar] [CrossRef] [PubMed]
  19. Marenco, M.; Canziani, L.; De Matteis, G.; Cavenaghi, G.; Aprile, C.; Lodola, L. Chemical and Physical Characterisation of Human Serum Albumin Nanocolloids: Kinetics, Strength and Specificity of Bonds with 99mTc and 68Ga. Nanomaterials 2021, 11, 1776. [Google Scholar] [CrossRef]
  20. Hunt, A.P.; Frier, M.; Johnson, R.A.; Berezenko, S.; Perkins, A.C. Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging. Eur. J. Pharm. Biopharm. 2006, 62, 26–31. [Google Scholar] [CrossRef]
  21. Schembri, G.P.; Roach, P.J.; Bailey, D.L.; Freeman, L. Artifacts and Anatomical Variants Affecting Ventilation and Perfusion Lung Imaging. Semin. Nucl. Med. 2015, 45, 373–391. [Google Scholar] [CrossRef] [PubMed]
  22. Shanehsazzadeh, S.; Jalilian, A.R.; Lahooti, A.; Geramifar, P.; Beiki, D.; Yousefnia, H.; Rabiee, A.; Mazidi, M.; Mirshojaei, S.F.; Maus, S. Preclinical Evaluation of 68Ga-MAA from Commercial Available 99mTc-MAA Kit. Iran. J. Pharm. Res. IJPR 2017, 16, 1415–1423. [Google Scholar] [PubMed]
  23. Malone, L.A.; Malone, J.F.; Ennis, J.T. Kinetics of technetium 99m labelled macroaggregated albumin in humans. Br. J. Radiol. 1983, 56, 109–112. [Google Scholar] [CrossRef] [PubMed]
  24. Even, G.A.; Green, M.A. Gallium-68-labeled macroaggregated human serum albumin, 68Ga-MAA. Int. J. Radiat. Appl. Instrum. Part B Nucl. Med. Biol. 1989, 16, 319–321. [Google Scholar] [CrossRef]
  25. Watanabe, N.; Shirakami, Y.; Tomiyoshi, K.; Oriuchi, N.; Hirano, T.; Yukihiro, M.; Inoue, T.; Endo, K. Indirect labeling of macroaggregated albumin with indium-111 via diethylenetriaminepentaacetic acid. Nucl. Med. Biol. 1996, 23, 595–598. [Google Scholar] [CrossRef]
  26. Hnatowich, D.J. Labeling of tin-soaked albumin microspheres with 68Ga. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 1976, 17, 57–60. [Google Scholar]
  27. Velikyan, I. Prospective of 68Ga-radiopharmaceutical development. Theranostics 2014, 4, 34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Mathias, C.J.; Green, M.A. A convenient route to [68Ga]Ga-MAA for use as a particulate PET perfusion tracer. Appl. Radiat. Isot. Incl. Data Instrum. Methods Use Agric. Ind. Med. 2008, 66, 1910–1912. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Jain, A.; Subramanian, S.; Pandey, U.; Sarma, H.D.; Ram, R.; Dash, A. In-house preparation of macroaggregated albumin (MAA) for 68Ga labeling and its comparison with comercially available MAA. J. Radioanal. Nucl. Chem. 2016, 308, 817–824. [Google Scholar] [CrossRef]
  30. Hayes, R.L.; Carlton, J.E.; Kuniyasu, Y. A new method for labeling microspheres with 68Ga. Eur. J. Nucl. Med. 1981, 6, 531–533. [Google Scholar] [CrossRef]
  31. Maziere, B.; Loc’h, C.; Steinling, M.; Comar, D. Stable labelling of serum albumin microspheres with gallium-68. Int. J. Radiat. Appl. Instrum. Part A Appl. Radiat. Isot. 1986, 37, 360–361. [Google Scholar] [CrossRef]
  32. Maus, S.; Buchholz, H.G.; Ament, S.; Brochhausen, C.; Bausbacher, N.; Schreckenberger, M. Labelling of commercially available human serum albumin kits with 68Ga as surrogates for 99mTc-MAA microspheres. Appl. Radiat. Isot. Incl. Data Instrum. Methods Use Agric. Ind. Med. 2011, 69, 171–175. [Google Scholar] [CrossRef] [PubMed]
  33. Ament, S.J.; Maus, S.; Reber, H.; Buchholz, H.G.; Bausbacher, N.; Brochhausen, C.; Graf, F.; Miederer, M.; Schreckenberger, M. PET lung ventilation/perfusion imaging using 68Ga aerosol (Galligas) and 68Ga-labeled macroaggregated albumin. Recent Results Cancer Res. 2013, 194, 395–423. [Google Scholar]
  34. Amor-Coarasa, A.; Milera, A.; Carvajal, D.; Gulec, S.; McGoron, A.J. Lyophilized Kit for the Preparation of the PET Perfusion Agent [68Ga]-MAA. Int. J. Mol. Imaging 2014, 2014, 269365. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Mueller, D.; Kulkarni, H.; Baum, R.P.; Odparlik, A. Rapid Synthesis of 68Ga-labeled macroaggregated human serum albumin (MAA) for routine application in perfusion imaging using PET/CT. Appl. Radiat. Isot. Incl. Data Instrum. Methods Use Agric. Ind. Med. 2017, 122, 72–77. [Google Scholar] [CrossRef] [PubMed]
  36. Persico, M.G.; Marenco, M.; De Matteis, G.; Manfrinato, G.; Cavenaghi, G.; Sgarella, A.; Aprile, C.; Lodola, L. 99mTc-68Ga-ICG-Labelled Macroaggregates and Nanocolloids of Human Serum Albumin: Synthesis Procedures of a Trimodal Imaging Agent Using Commercial Kits. Contrast Media Mol. Imaging 2020, 2020, 3629705. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Gültekin, A.; Cayir, M.C.; Ugur, A.; Bir, F.; Yüksel, D. Detection of Pulmonary Embolism with Gallium-68 Macroaggregated Albumin Perfusion PET/CT: An Experimental Study in Rabbits. Contrast Media Mol. Imaging 2020, 2020, 5607951. [Google Scholar] [CrossRef]
  38. Ayse, U.; Aziz, G.; Dogangun, Y. High-Efficiency Cationic Labeling Algorithm of Macroaggregated Albumin with 68Gallium. Nucl. Med. Mol. Imaging 2021, 55, 79–85. [Google Scholar] [CrossRef] [PubMed]
  39. Blanc-Béguin, F.; Masset, J.; Robin, P.; Tripier, R.; Hennebicq, H.; Guilloux, V.; Vriamont, C.; Wargnier, C.; Cogulet, V.; Eu, P.; et al. Fully automated 68Ga-labeling and purification of macroaggregated albumin particles for lung perfusion PET imaging. Front. Nucl. Med. 2021, 1, 10. [Google Scholar] [CrossRef]
  40. Velikyan, I. 68Ga-Based radiopharmaceuticals: Production and application relationship. Molecules 2015, 20, 12913–12943. [Google Scholar] [CrossRef] [Green Version]
  41. Zhernosekov, K.P.; Filosofov, D.V.; Baum, R.P.; Aschoff, P.; Bihl, H.; Razbash, A.A.; Jahn, M.; Jennewein, M.; Rosch, F. Processing of generator-produced 68Ga for medical application. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2007, 48, 1741–1748. [Google Scholar] [CrossRef] [PubMed]
  42. Harris, W.R.; Pecoraro, V.L. Thermodynamic binding constants for gallium transferrin. Biochemistry 1983, 22, 292–299. [Google Scholar] [CrossRef]
  43. Kotzerke, J.; Andreeff, M.; Wunderlich, G.; Wiggermann, P.; Zophel, K. Ventilation-perfusion-lungscintigraphy using PET and 68Ga-labeled radiopharmaceuticals. Nuklearmedizin. Nucl. Med. 2010, 49, 203–208. [Google Scholar]
  44. Senden, T.J.; Moock, K.H.; Gerald, J.F.; Burch, W.M.; Browitt, R.J.; Ling, C.D.; Heath, G.A. The physical and chemical nature of technegas. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 1997, 38, 1327–1333. [Google Scholar]
  45. Lloyd, J.J.; Shields, R.A.; Taylor, C.J.; Lawson, R.S.; James, J.M.; Testra, H.J. Technegas and Pertechnegas particle size distribution. Eur. J. Nucl. Med. 1995, 22, 473–476. [Google Scholar] [CrossRef]
  46. Mackey, D.W.; Burch, W.M.; Dance, I.G.; Fisher, K.J.; Willett, G.D. The observation of fullerenes in a Technegas lung ventilation unit. Nucl. Med. Commun. 1994, 15, 430–434. [Google Scholar] [CrossRef]
  47. Burch, W.M.; Sullivan, P.J.; McLaren, C.J. Technegas—A new ventilation agent for lung scanning. Nucl. Med. Commun. 1986, 7, 865–871. [Google Scholar] [CrossRef]
  48. Monaghan, P.; Provan, I.; Murray, C.; Mackey, D.W.; Van der Wall, H.; Walker, B.M.; Jones, P.D. An improved radionuclide technique for the detection of altered pulmonary permeability. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 1991, 32, 1945–1949. [Google Scholar]
  49. Isawa, T.; Teshima, T.; Anazawa, Y.; Miki, M.; Motomiya, M. Technegas for inhalation lung imaging. Nucl. Med. Commun. 1991, 12, 47–55. [Google Scholar] [CrossRef]
  50. Isawa, T.; Teshima, T.; Anazawa, Y.; Miki, M.; Soni, P.S. Technegas versus krypton-81m gas as an inhalation agent. Comparison of pulmonary distribution at total lung capacity. Clin. Nucl. Med. 1994, 19, 1085–1090. [Google Scholar]
  51. Pourchez, J.; Albuquerque-Silva, I.M.D.; Cottier, M.; Clotagatide, A.; Vecellio, L.; Durand, M.; Dubois, F. Generation and characterization of radiolabelled nanosized carbonaceous aerosols for human inhalation studies. J. Aerosol Sci. 2013, 55, 1–11. [Google Scholar] [CrossRef] [Green Version]
  52. Scalzetti, E.M.; Gagne, G.M. The transition from technegas to pertechnegas. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 1995, 36, 267–269. [Google Scholar]
  53. Mackey, D.W.; Jackson, P.; Baker, R.J.; Dasaklis, C.; Fisher, K.J.; Magee, M.; Bush, V.; Burch, W.M.; Van der Wall, H.; Willett, G.D. Physical properties and use of pertechnegas as a ventilation agent. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 1997, 38, 163–167. [Google Scholar]
  54. Fanti, S.; Compagnone, G.; Pancaldi, D.; Franchi, R.; Corbelli, C.; Marengo, M.; Onofri, C.; Galassi, R.; Levorato, M.; Monetti, N. Evaluation of lung clearance of inhaled pertechnegas. Ann. Nucl. Med. 1996, 10, 147–151. [Google Scholar] [CrossRef]
  55. Sanchez-Crespo, A. Lung Scintigraphy in the Assessment of Aerosol Deposition and Clearance. Semin. Nucl. Med. 2019, 49, 47–57. [Google Scholar] [CrossRef]
  56. Hartmann, I.J.; Hagen, P.J.; Stokkel, M.P.; Hoekstra, O.S.; Prins, M.H. Technegas Versus 81mKr Ventilation–Perfusion Scintigraphy: A Comparative Study in Patients with Suspected Acute Pulmonary Embolism. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2001, 42, 8. [Google Scholar]
  57. Möller, W.; Felten, K.; Seitz, J.; Sommerer, K.; Takenata, S.; Wiebert, P.; Philipson, K.; Svartengren, M.; Kreyling, W.G. A generator for the production of radiolabelled ultrafine carbonaceous particles for deposition and clearance studies in the respiratory tract. J. Aerosol Sci. 2006, 37, 631–644. [Google Scholar] [CrossRef]
  58. Strong, J.C.; Agnew, J.E. The particle size distribution of technegas and its influence on regional lung deposition. Nucl. Med. Commun. 1989, 10, 425–430. [Google Scholar] [CrossRef]
  59. Lemb, M.; Oei, T.H.; Eifert, H.; Gunther, B. Technegas: A study of particle structure, size and distribution. Eur. J. Nucl. Med. 1993, 20, 576–579. [Google Scholar] [CrossRef]
  60. Blanc-Beguin, F.; Elies, P.; Robin, P.; Tripier, R.; Kervarec, N.; Lemarie, C.A.; Hennebicq, S.; Tromeur, C.; Cogulet, V.; Salaun, P.Y.; et al. 68Ga-Labelled Carbon Nanoparticles for Ventilation PET/CT Imaging: Physical Properties Study and Comparison with Technegas®. Mol. Imaging Biol. 2021, 23, 62–69. [Google Scholar] [CrossRef]
  61. Oehme, L.; Zophel, K.; Golgor, E.; Andreeff, M.; Wunderlich, G.; Brogsitter, C.; de Abreu, M.G.; Kotzerke, J. Quantitative analysis of regional lung ventilation and perfusion PET with 68Ga-labelled tracers. Nucl. Med. Commun. 2014, 35, 501–510. [Google Scholar] [CrossRef]
  62. Borges, J.B.; Velikyan, I.; Langstrom, B.; Sorensen, J.; Ulin, J.; Maripuu, E.; Sandstrom, M.; Widstrom, C.; Hedenstierna, G. Ventilation distribution studies comparing Technegas and “Gallgas” using 68GaCl3 as the label. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2011, 52, 206–209. [Google Scholar] [CrossRef] [Green Version]
  63. Bailey, D.L.; Eslick, E.M.; Schembri, G.P.; Roach, P.J. 68Ga PET Ventilation and Perfusion Lung Imaging-Current Status and Future Challenges. Semin. Nucl. Med. 2016, 46, 428–435. [Google Scholar] [CrossRef]
Pharmaceuticals 15 00518 g001 550
Figure 1. Key points of MAA labelling with 68Ga.
Figure 1. Key points of MAA labelling with 68Ga.
Pharmaceuticals 15 00518 g001
Pharmaceuticals 15 00518 g002 550
Figure 2. Schematic representation of the [68Ga]Ga-MAA purification stage based on the process by Blanc-Béguin et al. Used with permission from Blanc-Béguin et al. [39].
Figure 2. Schematic representation of the [68Ga]Ga-MAA purification stage based on the process by Blanc-Béguin et al. Used with permission from Blanc-Béguin et al. [39].
Pharmaceuticals 15 00518 g002
Table
Table 1. [68Ga]Ga-MAA labelling conditions of various methods described in the literature.
Table 1. [68Ga]Ga-MAA labelling conditions of various methods described in the literature.
Albumin Particles Labelled68Ga Eluate
Pre-Purification		Labelling ConditionsRadiolabelling Yield (%)Process Duration (min)Manual/Automated Process
Nature and OriginWashed/Non-WashedYes/NoMethod UsedpHBufferHeating Time (min)T °C
Hnatowich et al. [26]HSA microspheres. Commercial kit.Non-washedYesAnion exchange chromatography2.6–3 1540–6065.040Manual
Hayes et al. [30]HSA microspheres.
Commercial kit.		Non-washedYesAnion exchange chromatography4.8Sodium acetate solution103797.4 ± 1.0 Manual
Maziere et al. [31]HSA microspheres.
Commercial kit.		Non-washedYesPre-concentration4.7 208593.2 ± 2.540Manual
Even and Green [24]MAA. Commercial kit.WashedYesPre-concentration4.7Sodium acetate buffer1574 ± 177.0–97.0 Manual
Mathias et al. [28]MAA. Commercial kit.Washed 5–6Sodium acetate solution157581.6 ± 5.325Manual
Maus et al. [32]MAA. Commercial kit.WashedYesFractionation4HEPES207585.0 ± 2.030Manual
Hofman et al. [6]MAA. Commercial kit.WashedYesSCX cartridge6.5Sodium acetate solution570≥90.0 Manual
Ament et al. [33]MAA. Commercial kit.WashedYesFractionation4HEPES207585.0 ± 2.0 Manual
Amor-Coarasa et al. [34]MAA. Commercial kit.WashedNo 4.7Sodium acetate solution157578.3 ± 3.1 Manual
YesCombination of chromatographic exchange resins (cationic then anionic)4.7Sodium acetate solution157597.6 ± 1.5 Manual
Jain et al. [29]MAA. Homemade with and without SnCl2 No 6 157577.6 Manual
Mueller et al. [35]MAA. Commercial kit.Washed and non-washedYesSCX cartridge4.5Sodium acetate buffer10115Not mentioned (non-washed)
75.0 (washed)		20 (manual) 14 (automated)Manual
and automated
Shannehsazzadeh et al. [22]MAA. Commercial kit.WashedYesFractionation4HEPES87590.0 -95.0 Manual
Persico et al. [36]MAA. Commercial kit.WashedYesSCX cartridge6–6.5Sodium acetate buffer154097.0 Manual
and automated
Gultekin et al. [37]MAA. Commercial kit.WashedYesPSH+ cartridge4–5HEPES79080.0 Manual
Ayșe et al. [38]MAA. Commercial kit.WashedYesPSH+ cartridge4–5HEPES79085.0 ± 3.016Automated
Blanc-Béguin et al. [39]MAA. Commercial kit.Non washedNo 4.3Sodium acetate solution56096.0 ± 1.715Automated
Table
Table 2. Process of [68Ga]Ga-MAA purification and radiochemical purity according to the various authors.
Table 2. Process of [68Ga]Ga-MAA purification and radiochemical purity according to the various authors.
[68Ga]Ga-MAA Purification ConditionsRadiochemical Purity (%)
Process of PurificationManual/Automated
Maziere et al. [31]CentrifugationManual99.9
Even and Green [24]CentrifugationManual89.0 ± 5.0–98.4 ± 0.3
Mathias et al. [28]CentrifugationManual99.8 ± 0.1
Maus et al. [32]Sep-Pak C18 cartridgeManual>97.0
Ament et al. [33]CentrifugationManual>97.0
Amor-Coarasa et al. [34]CentrifugationManual>95.0
Jain et al. [29]CentrifugationManual98.0 ± 0.8
Mueller et al. [35]No purification >95.0
Shannehsazzadeh et al. [22]CentrifugationManual100.0
Persico et al. [36]No purification 97.0
Gultekin et al. [37]CentrifugationManual99.0
Ayșe et al. [38]No purification 99.0
Blanc-Béguin et al. [39]FiltrationAutomated99.0 ± 0.6
Table
Table 3. Summary of important factors of the switch from 99mTc to 68Ga.
Table 3. Summary of important factors of the switch from 99mTc to 68Ga.
[99mTc]Tc-MAA[68Ga]Ga-MAA
Labelling conditions
pH64–6.5
Heating temperature (°C)Room temperature40–115 °C
Heating time (min)05–20 min
Total labelling time20 min15–40 min
Size
µm10.0–90.015.0–75.0
Labelled MAA suspension stability
hours83
Labelled MAA in vitro serum stability
hours241
BiodistributionIn humansIn animals
Lungs uptake%98.0 [23]
timeImmediately after injection
%86.6 ± 0.7 [34]98.6 ± 0.7 [34]
time2 h post-injection
Kidney uptake%3.6 ± 2.1 [23]1.6 ± 0.4 (right kidney), 1.4 ± 0.2 (left kidney) [34]
time3 h after injection4 h after injection
Bladder uptake%5.1 ± 4.014 ± 1.7
time3 h after injection4 h after injection [34]
Stomach uptake%3.5 ± 2.5
time4.4 after injection
Table
Table 4. 99mTc and 68Ga-labelled carbon nanoparticle size, shape and structure according to the literature.
Table 4. 99mTc and 68Ga-labelled carbon nanoparticle size, shape and structure according to the literature.
Labelled Carbon Primary Nanoparticle Size (nm)Labelled Carbon Secondary Aggregate Size (nm)Count Median Diameter (nm)Labelled Carbon Nanoparticle Thickness (nm)Shape, Structure and PropertiesPhysical Properties
99mTc labellingBurch et al. [47]≤5.0
Strong et al. [58] 140.0 ± 1.5
Isawa et al. [49]≤200.0
Lemb et al. [59]12.5 ± 1.65 (7–23)118.0 (60–160) Primary hexagonally structured graphite particlesHydrophobic properties. Inert properties
Mackey et al. [46] Fullerenes
Lloyd et al. [45] 100.0–300.0158.0 ± 1.5
Senden et al. [44]30.0–60.0 5.0Thin hexagonal platelets with graphite planes oriented parallel to the Tc surfaceBiological inertness
Möller et al. [57]10.0100.0–200.0 Hygroscopic properties
Pourchez et al. [51]40.0 ± 2.9 Hexagonal platelets of metallic technetium closely encapsulated with a thin layer of graphitic carbonHygroscopic properties
Blanc-Béguin et al. [60]20.9 ± 7.2 Thin hexagonal platelets with graphite planes oriented parallel to the Tc surface
68Ga labellingBlanc-Béguin et al. [60]22.4 ± 10Several hundreds Hexagonal shape
Layered structure
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Blanc-Béguin, F.; Hennebicq, S.; Robin, P.; Tripier, R.; Salaün, P.-Y.; Le Roux, P.-Y. Radiopharmaceutical Labelling for Lung Ventilation/Perfusion PET/CT Imaging: A Review of Production and Optimization Processes for Clinical Use. Pharmaceuticals 2022, 15, 518. https://doi.org/10.3390/ph15050518

AMA Style

Blanc-Béguin F, Hennebicq S, Robin P, Tripier R, Salaün P-Y, Le Roux P-Y. Radiopharmaceutical Labelling for Lung Ventilation/Perfusion PET/CT Imaging: A Review of Production and Optimization Processes for Clinical Use. Pharmaceuticals. 2022; 15(5):518. https://doi.org/10.3390/ph15050518

Chicago/Turabian Style

Blanc-Béguin, Frédérique, Simon Hennebicq, Philippe Robin, Raphaël Tripier, Pierre-Yves Salaün, and Pierre-Yves Le Roux. 2022. "Radiopharmaceutical Labelling for Lung Ventilation/Perfusion PET/CT Imaging: A Review of Production and Optimization Processes for Clinical Use" Pharmaceuticals 15, no. 5: 518. https://doi.org/10.3390/ph15050518

APA Style

Blanc-Béguin, F., Hennebicq, S., Robin, P., Tripier, R., Salaün, P. -Y., & Le Roux, P. -Y. (2022). Radiopharmaceutical Labelling for Lung Ventilation/Perfusion PET/CT Imaging: A Review of Production and Optimization Processes for Clinical Use. Pharmaceuticals, 15(5), 518. https://doi.org/10.3390/ph15050518

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop